If you experience minimal side effects and are losing weight steadily, your prescribed dose may advance from 2.5 mg to 5 mg, then 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg
This raises the possibility that GLP-1s could influence the gut-immune axis, which is often disrupted in autoimmune diseases
But why now
What the Clinical Evidence Shows While large-scale randomized controlled trials specifically measuring testosterone as a primary endpoint in tirzepatide users are still emerging, the available evidence is encouraging: The SURMOUNT trials demonstrated average weight losses of 15-22.5% of body weight, a degree of fat reduction strongly associated with testosterone recovery in men with obesity-related hypogonadism (Jastreboff et al., 2022, NEJM )
Medicaid Coverage by State Medicaid coverage for weight loss medication varies dramatically by state, and this variability is one of the most significant equity issues in obesity medicine